Navigation Links
Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be,Presented at American Thoracic Society International Conference

and clinical trials are long, expensive and uncertain processes, (ii) because the NKTR-061 program is in the early phases of clinical development, the risk of failure is high and can occur at any stage of development, (iii) the company's ability to obtain regulatory approval of NKTR-061 and (iv) there can be no assurance that the company's patent applications for NTKR-061 will issue; patents that have issued will be enforceable; or that intellectual property licenses from third parties may not be required in the future. Other important risks and uncertainties are detailed in the company's reports and other filings with the SEC, including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Actual results could differ materially from the forward-looking statements contained in this press release. The company undertakes no obligation to update forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact

Nektar
Tim Warner, 650-283-4915
twarner@nektar.com
or
Stephan Herrera, 415-488-7699
sherrera@nektar.com


'"/>




Page: 1 2 3

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:11/25/2008)...Nov. 25 Proteolix, Inc., a,leader...utics that target,protein degradation pathways in...that data from two ongoing Phase 2 clinical trials...nted at the upcoming 50th Annual Meeting of the,A...is the first in a new class,of specific proteasom...
(Date:11/25/2008)...ical Trial to Assess Survival of Patients Receivin...ectable Hepatocellular Carcinoma , , BELLEV...Oncology, Inc. (LSO) today announced the completio... of Light Infusion Therapy(TM) (Litx(TM)) as a tre...HCC), also known as hepatoma or primary liver canc...
(Date:11/24/2008)...Newswire/ -- Domino,s Pizza (NYSE: DPZ ), the,r...ng up to raise dough for,the kids of St. Jude Chi...,Thanks and Giving campaign. Domino,s customers wi...nt of purchase to benefit the children of St. Jude...one or when ordering online at, www.dominos.com ....
(Date:11/24/2008)...ion leadership and long-term commitment to hepatit...PRNewswire-FirstCall/ -- Schering-Plough Corporati... on boceprevir, its lead investigational oral hepa...development. The company believes boceprevir has ...lass protease inhibitor for treating chronic hepat...
Breaking Medicine Technology:Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 2Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9Gene Mutation Puts Some Kids at Risk for Tobacco Addiction 24151 1Gene Mutation Puts Some Kids at Risk for Tobacco Addiction 24151 2U S Health Care Still Ill Survey Finds 24149 1U S Health Care Still Ill Survey Finds 24149 2U S Health Care Still Ill Survey Finds 24149 3Aethons Train Themed Delivery Robot Available To Childrens Hospitals Nationwide 24147 1Aethons Train Themed Delivery Robot Available To Childrens Hospitals Nationwide 24147 2WeissComm Partners Ranks Among Top 5 Best U S Midsize PR Agencies to Work For 24145 1WeissComm Partners Ranks Among Top 5 Best U S Midsize PR Agencies to Work For 24145 2
... Fail to Demonstrate Meaningful Placebo Adjusted W...W YORK, July 09, 2007 /PRNewswire-FirstCall/ -- Ma...lts of the company,s two,Phase 2a clinical trials ...andomized, double-blind, placebo-controlled studie...besity, demonstrated no,statistically or clinicall...
...ction of rHuPH20 with Humira Estimated to Increase...lity from 64% to 100%,-, SAN DIEGO, July 09, 2007 ...nc. , a biopharmaceutical company developing and,c...nounced that,final results of the Enhanze(TM) Tech...ption and bioavailability of a,representative comm...
Other Medicine Technology:Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for,Oral Oleoyl-estrone 2Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for,Oral Oleoyl-estrone 3Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for,Oral Oleoyl-estrone 4Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 2Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 3Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 4Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 5
(Date:12/2/2008)...f., Dec. 2 Internationally recogni...an invited speaker for this,year,s annual meeting... (Photo: http://www.newscom.com/cgi-bin/prnh...y is minimally invasive (or ,Goldilocks,) anesthes...d ,PK 101, minimally invasive,anesthesia for mini...
(Date:12/2/2008)...ica, Dec. 2 The Healthcare group a...ost.com ) is pleased to announce that,it will be ...dustry in,sub-Saharan Africa on Friday 12 Decembe...www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , ...althcare services is a,relatively novel concept i...
(Date:12/2/2008)... For many families, the problem with the holi...vides insight into how caregivers of aging parents...der care experience. , Sa...amilies the stress of the holiday season is family...er care expert Esther Koch , founder of Encore M...
(Date:12/2/2008)... Orion Health announces that the SouthEast Al..., Alaska, has selected the Rhapsody™ Integra...h record, radiology, pharmacy, laboratory and busi... plans to extend connectivity to statewide systems... registry) and AKAIMS (an MIS and clinical documen...
Breaking Medicine News(10 mins):Health News:The Future of Financing Health Services in Africa 2Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 2Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 3Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 2Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 3
...ished in The Lancet on adolescent health, the curr...ompared to their parents.// The infections of the ...en way to venereal diseases, drinking, smoking, ob...er lining to this issue is that these conditions c...
...eart disease medicine of Sanofi-Aventis will be ma... the pharma company on Tuesday.// As per the offe...approved plans to buy or make imitated version of ...drug firm states that indigenous making of the hea...
...e the latest trend which is making waves in the he...arn and develop their skills to make sure the eval... of patients. More than 170 physician performanc...a, heart failure and emergency care through the Ph...
... aerated drink manufacturers Pepsico and Coca Cola...// The Ganguly report had deduced that pesticide r...Pepsico and Coca cola should be furnished within s...a civil society group had filed a public interest ...
Other Medicine News:
...ased, 2-8-channel system for measuring bioelectric...optic nerve. The basic set comprises: computer dev...ioelectrical amplifier, electrodes and checkerboar...o install. The recorded curves are displayed on a ...
A sophisticated research tool that allows to see the fundus picture of the area which is being stimulated. Besides it also includes the refractive pupil camera enabling the examiner to switch between
5 mm
Cannula and irrigation extension. Overall Length 150 mm (6.25"). Light Curve.
Medicine Products: